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PEXPEDITED REVIEWS
Increased Late Mortality After
Sirolimus-Eluting Stents Versus Bare-Metal
Stents in Diseased Saphenous Vein Grafts
Results From the Randomized DELAYED RRISC Trial
Paul Vermeersch, MD, Pierfrancesco Agostoni, MD, Stefan Verheye, MD, PHD,
Paul Van den Heuvel, MD, Carl Convens, MD, Frank Van den Branden, MD,
Glenn Van Langenhove, MD, PHD, for the DELAYED RRISC (Death and Events at Long-term
follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with
Cypher stent) Investigators
Antwerp, Belgium
Objectives We sought to provide long-term follow-up data of sirolimus-eluting stents (SES) versus bare-metal stents (BMS) in sa-
phenous vein grafts (SVG) from the RRISC (Reduction of Restenosis In Saphenous vein grafts with Cypher) trial.
Background We have previously shown that, in SVG, the use of SES reduces 6-month restenosis and repeated revasculariza-
tion procedures versus the use of BMS. These data are consistent with trials in native coronary arteries. How-
ever, recently published long-term follow-up data of these trials have revealed an increased risk of adverse
events (particularly very late stent thrombosis) after SES.
Methods A total of 75 patients with 96 SVG lesions were randomized to SES versus BMS. All patients underwent clinical
follow-up up to 3 years. Specific outcomes assessed in this secondary post-hoc analysis were all-cause mortality,
myocardial infarction, and target vessel revascularization.
Results Thirty-eight patients received 60 SES for 47 lesions, whereas 37 patients received 54 BMS for 49 lesions. At a me-
dian follow-up time of 32 months (interquartile range 26.5 to 36 months), 11 deaths (7 cardiac, of which 1 was
caused by very late stent thrombosis and, 3 were sudden) occurred after SES (29% [95% confidence interval (CI) 17%
to 45%]) versus 0 after BMS (0% [95% CI 0% to 9%]) with an absolute difference of 29% ([95% CI 14% to 45%], p
0.001). The rates of myocardial infarction and target vessel revascularization were not different: 18% and 34% after
SES, respectively, versus 5% and 38% after BMS, respectively (p 0.15 and p  0.74, respectively).
Conclusions In this secondary post-hoc analysis, BMS were associated with lower long-term mortality than SES for SVG dis-
ease. Also, the 6-month reduction in repeated revascularization procedures with SES was lost at longer-term
follow-up. (RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent;
http://clinicaltrials.gov/ct/show/NCT00263263?order1; NCT00263263) (J Am Coll Cardiol 2007;50:261–7)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.010i
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lirolimus-eluting stents (SES) have been shown to reduce
-month to 1-year major adverse cardiac events as compared
ith bare-metal stents (BMS) in native coronary arteries,
ainly by considerably decreasing the rate of repeated
evascularization procedures caused by the restenotic process
n the stent (1–5). Conversely, recent data on long-term
2 years) clinical follow-up have raised the issue of an
rom the Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Antwerp,
elgium. Drs. Vermeersch and Agostoni contributed equally to this work.w
Manuscript received April 2, 2007; revised manuscript received May 18, 2007,
ccepted May 21, 2007.ncreased rate of “hard” end points, such as death and
yocardial infarction (MI), after SES, potentially due to an
ugmented risk of late stent thrombosis (6–10) and to an
ncrease in noncardiac-related deaths (11).
See page 268
Despite this large body of evidence, lesions in saphenous
ein grafts (SVG) have been poorly represented if not totally
xcluded in pivotal drug-eluting stent trials. However, this
esion subset represents a consistent proportion of lesions in
hich percutaneous procedures are performed, up to 10% to
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effective and satisfactory thera-
pies are still lacking, as peripro-
cedural complications and long-
term events remain elevated
(12,13).
We have recently shown that
the use of SES is effective in
reducing 6-month angiographic
and clinical parameters of reste-
nosis with respect to BMS in
SVG (14). However, because of
the lack of long-term data in
patients with this type of lesion,
and to offer additional informa-
ion to the current debate on the safety of SES, we
erformed a clinical follow-up evaluation of the patients
nrolled in the RRISC (Reduction of Restenosis In Saphe-
ous vein grafts with Cypher sirolimus-eluting stent) trial up
o 3 years, focusing specifically on all-cause mortality.
ethods
he RRISC trial is a randomized study approved by the
ocal ethics committee, and its design and main results have
een previously described (14). The study was double blind
ntil the moment of primary analysis (14). Blinding was
aintained in the follow-up period for patients and refer-
ing clinical cardiologists and general practitioners but not
or the interventional cardiologists performing the index
rocedure and analyzing the data. Thus, the current analysis
s single blind.
Between September 2003 and November 2004, 75 pa-
ients with a history of previous coronary artery bypass
urgery and with 96 “de novo” target lesions localized in 80
iseased SVG with a reference vessel diameter 2.5 and
4.0 mm were enrolled. All patients provided written
nformed consent before the index procedure.
Patients were allocated randomly in a 1:1 ratio to treat-
ent with Cypher SES or BX-Velocity BMS (both from
ordis, Johnson & Johnson, Miami Lakes, Florida). Details
n the randomization process have been described (14).
cetylsalicylic acid (100 to 300 mg/day) was given daily and
lopidogrel (loading dose of 300 mg, 6 to 48 h before the
rocedure and 75 mg/day thereafter) was administered for
t least 2 months in all patients. Prolonged therapy with
lopidogrel or ticlopidine (250 mg twice per day) instead of
lopidogrel was left to the decision of the physician taking
are of the patient (who was also blinded to the type of stent
mplanted, as previously described). Clinical follow-up was
cheduled at 1 and 6 months. Coronary angiography was
epeated at 6 months.
ong-term follow-up. In September 2006, we obtained a
ew approval from the Ethics Committee at Antwerp
ardiovascular Institute Middelheim to prolong the
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
MI  myocardial infarction
SES  sirolimus-eluting
stent(s)
SVG  saphenous vein
graft(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationollow-up duration of the RRISC trial in order to directly uuery patients about their status and the occurrence of
urther events after the initial 6 months. We mailed an
dditional informed consent to all patients (or to the
elatives) to obtain permission to use their data. Once we
eceived all of the signed informed consents, beginning in
ovember 2006 we contacted every patient by phone and
nvestigated the occurrence of events such as death, MI,
epeated revascularizations, new hospitalizations, and addi-
ional ambulatory visits using a prespecified questionnaire.
f a positive result for any of the aforementioned events was
btained, we asked the patient (or relatives) to send us the
ecords related to each event. If the patient was hospitalized
n our institution, we reviewed our internal clinical records.
n case of hospitalization in other hospitals, we formally
equested the clinical records of interest. To ascertain
urvival status, the National Civil Registry was further
ontacted for final confirmation of the events.
nd points and definitions. The new post-hoc main end
oint of this secondary long-term follow-up analysis was
ll-cause mortality. Additional end points were the rate of
ajor adverse cardiac events, which included death, all
onfatal major MI (also periprocedural), and target vessel
evascularization (TVR). All deaths were considered cardiac
nless a clear noncardiac cause could be established. Spe-
ifically, any unexpected or unwitnessed death was consid-
red of cardiac origin. Periprocedural MI was defined as an
levation of creatine kinase-MB activity3 times above the
pper limit of normal (16 U/l in our institution). Non-
eriprocedural MI was defined as a new ischemic event with
reatine kinase-MB 2 times the upper limit of normal, or
he electrocardiographic presence of new pathological Q
aves. Target lesion revascularization (TLR) was defined as
repeated revascularization procedure (either percutaneous
oronary intervention or coronary bypass surgery), as the
esult of restenosis in the stented segment. We defined TVR
s a new revascularization procedure in the target vessel, also
ncluding TLR. Stent thrombosis was defined as early (30
ays), late (1 year), and very late (1 year) and as definite,
robable, or possible. Definite stent thrombosis required an
cute coronary ischemic event associated to angiographic or
utopsy documentation of partial or total stent occlusion or
hrombosis. Probable stent thrombosis included any unex-
lained death within 30 days after the index procedure and
ny target vessel MI (also without angiographic documen-
ation) any time during follow-up. Possible stent thrombosis
ncluded any unexplained death occurring 30 days after
he index procedure (15). All the clinical events were
djudicated by an independent clinical events committee
naware of the patients’ treatment assignment.
tatistical analysis. Continuous data are expressed as
eans  standard deviation or as medians (interquartile
ange) as appropriate, whereas dichotomous data are sum-
arized as frequencies. Parametric Student t or nonpara-
etric Mann-Whitney U test (as appropriate) and chi-
quare or the Fisher exact test (as appropriate) have been
sed, respectively, for unpaired continuous and for categor-
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July 17, 2007:261–7 Long-Term Follow-Up Data of SES Versus BMS in SVGcal variables, to analyze differences between the 2 study
rms. Additionally, survival analysis was graphically repre-
ented with the Kaplan-Meier technique, and groups were
ompared with the log rank test. A 2-sided p value 0.05
as considered significant for all tests. We also calculated
he 95% confidence limits for the single rates found and the
5% confidence intervals (CIs) for the absolute differences
omputed, using the Confidence Interval Analysis software
CIA, version 2.0.0) (16). The number needed to treat/
arm with 95% CI (extrapolated from the absolute differ-
nce) was computed for the occurrence of dichotomous
vents. Dr. Agostoni had full access to all of the data in the
tudy and takes responsibility for the integrity of the data
nd the accuracy of the data analysis.
esults
mong the 75 patients (with 96 lesions localized in 80
VG) enrolled in the RRISC trial, 38 patients received 60
ES for 47 lesions, whereas 37 patients received 54 BMS
or 49 lesions. The baseline clinical characteristics of the 2
roups are shown in Table 1 and are not different.
All patients were contacted between November and
ecember 2006. The median follow-up was not different
etween the 2 groups: 30.5 months (range 24 to 36 months)
or patients treated with SES versus 32 months (range 29 to
5.5 months) for patients treated with BMS (p  0.24).
aseline Clinical and Proceduralharacteristics of the Pati nts in the 2 Groups
Table 1 Baseline Clinical and ProceduralCharacteristics of the Patients in the 2 Groups
BMS (n  37) SES (n  38) p Value
Age, yrs 72 8 73 7 0.36
Men 33 (89%) 31 (82%) 0.36
Risk factors
Family history 29 (78%) 25 (66%) 0.23
Hypertension 21 (57%) 22 (58%) 0.84
Hypercholesterolemia 31 (84%) 33 (87%) 0.74
Current smoker 4 (11%) 2 (5%) 0.46
Diabetes mellitus 5 (14%) 6 (16%) 0.78
Body mass index, kg/m2 26.4 3.9 26.4 3.1 0.97
History of heart failure 7 (19%) 6 (16%) 0.72
Prior myocardial infarction 15 (41%) 17 (45%) 0.71
Prior coronary angioplasty 15 (41%) 12 (32%) 0.42
Unstable angina pectoris 19 (51%) 23 (60%) 0.41
Ejection fraction, % 72 12 68 18 0.37
Age of the grafts 12.6 5.9 12.4 4.6 0.92
No. of vein graft lesions
treated per patient
0.55
1 26 (70%) 29 (76%)
2 10 (27%) 9 (24%)
3 1 (3%) 0 (—)
No. of stents per patient 1.46 0.7 1.58 0.7 0.45
1 24 (65%) 20 (53%)
2 9 (24%) 14 (37%)
3 4 (11%) 4 (10%)i
ata are presented as numbers (percentages) or means  standard deviation.
BMS  bare-metal stent; SES  sirolimus-eluting stent.Death occurred in 11 patients after SES (29% [95%
onfidence limits 17% to 45%]) versus 0 after BMS (0% [0%
o 9%]) with an absolute difference of 29% (95% CI 14% to
5%, p  0.001) (Fig. 1). According to the number needed
o harm analysis, in our trial the treatment of 3.4 patients
95% CI 2.2 to 7.3) with SES resulted in 1 additional death
ith respect to treatment with BMS. Specifically, there
ere 7 cardiac deaths, of which 3 were sudden, possibly
elated to late or very late stent thrombosis according to our
efinition, and 1 was caused by an angiographically docu-
ented very late stent thrombosis 13 months after stent
mplantation, which caused a large MI leading to death.
ther details on the deceased patients are presented in
ables 2 and 3. Another additional very late angiographi-
ally documented SES thrombosis caused a nonfatal MI at
0 months after the index procedure, and it was successfully
reated percutaneously. The patient was on acetylsalicylic
cid, whereas he stopped clopidogrel 6 months after the
ndex procedure. Thus, the overall rate of definite angio-
raphically documented stent thrombosis was 5% in the
ES group (2 of 38, both very late) versus 0% in the BMS
roup (p  0.49), whereas the rate of any possible stent
hrombosis was 13% (5 of 38, 2 late and 3 very late) after
ES versus 0% after BMS (Fisher exact test 2-sided p value
0.054; log rank test  0.022).
Table 4 shows the overall rate of events that occurred in
he 2 groups at long-term follow-up and the medical
herapy taken by the patients at the moment of last
ollow-up. As evident, a nonsignificant trend toward an
ncreased rate of lesion- and vessel-related revascularization
rocedures is evident in the SES group after 6-month
ollow-up, neutralizing the initial 6-month benefit of SES
Figure 1 Survival Curves
Kaplan-Meier estimates for survival by type of randomized stent (dotted blue
line  bare-metal stent [BMS]; continuous red line  sirolimus-eluting stent
[SES]).n terms of TLR and TVR (Fig. 2). Potential confounding
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LR/TVR-related or the antiplatelet/hypocholesterolemic
herapy, were not significantly different and were well
alanced between the 2 groups.
iscussion
his extended analysis of the randomized double-blind
RISC trial evaluates the long-term clinical effects of SES
ersus BMS in patients with diseased SVG. The main
ndings are: 1) patients treated with SES showed a signif-
cant increase in total mortality; and 2) the benefit of SES in
erms of reduced revascularization procedures shown at 6
onths (14) was no longer evident up to 3 years.
linical and Angiographic Details on the SES Patients Who Died
Table 2 Clinical and Angiographic Details on the SES Patients
Patient
No.
Age,
yrs* Gender Diabetes*
Ejection
Fraction,
%*
Typ
Ang
17 81 M No 70 Unst
30 60 M No 70 Unst
37 79 M Yes 56 Unst
39 72 M No 72 Unst
42 83 M Yes 40 Unst
44 72 M Yes 32 Stab
46 69 F No 75 Unst
50 83 F Yes 75 Stab
52 66 M No 45 Stab
56 69 M No 51 Unst
58 61 F No NA Stab
At enrollment.
NA  not available; SES  sirolimus-eluting stent.
etails on the Specific Time-Courses and Reasons of Death in the
Table 3 Details on the Specific Time-Courses and Reasons of D
Patient
No.
Time of Death,
Months Caus
17 35 Sudden out-of-hospital death
30 33 Progressive multiple organ failu
grafting (documented late in
progression of other lesions)
37 30 Progressive Parkinson disease
39 19 Metastatic colon carcinoma
42 5 Progressive heart failure
44 11.5 Sudden out-of-hospital death
46 7.5 Sudden out-of-hospital death
50 23.5 Postoperative (aortic valve repl
bypass grafting for progressi
segment) infection (decubitu
52 16 Metastatic urothelial carcinoma
56 14.5 Progressive heart failure after m
thrombosis of the index sten
58 22 Progressive heart failure after p
myocardial infarction (no ste
but late stent thrombosis of
15 months before in the leftICD  automatic implantable cardioverter-defibrillator; ASA  acetylsalicylic acid; SES  sirolimus-elutGreat focus has recently been put on the evaluation of
ong-term follow-up of drug-eluting stents in native coro-
ary arteries, mainly after publication of original and meta-
nalytical studies showing a possible increase in “hard”
dverse events, specifically very late stent thrombosis, after
rug-eluting stent deployment with respect to BMS (6–11).
n light of these data, in December 2006, the U.S. Food and
rug Administration set up a panel to thoroughly assess the
ong-term values and drawbacks of drug-eluting stents. A
nal statement was made, in which the U.S. Food and Drug
dministration deemed the on-label use of drug-eluting
tents safe but warned against an increased risk of adverse
vents with off-label use (17,18). As percutaneous SVG
Died
Age of the
Grafts,
yrs*
No. of Lesions
Treated
No. of SES
Implanted
Total Length of
SES Implanted,
mm
10 2 2 51
14 2 2 51
21 1 3 49
11 1 2 31
15 1 2 51
18 2 3 74
12 1 1 23
9 1 2 51
14 1 2 61
20 1 1 33
11 1 1 23
atients
in the SES Patients
eath
Antithrombotic Therapy at the
Moment of Death
ASA, TP
er redo coronary artery bypass
restenosis and additional
ASA, TP
ASA, TP
—
(suspended 2 months before death
because of cachexia and anorexia)
TP
ASA, TP
TP, W
nt and redo coronary artery
isease not in the stented
ASA, TP
—
(suspended 1 month before death for
severe anemia requiring transfusion)
rdial infarction due to stent
ographically documented)
—
(suspended 1 week before MI for
planned knee operation)
rative (acute limb ischemia)
mbosis of the index stent,
itaxel-eluting stent implanted
—
(suspended 1 week before MI for
planned AICD change)Who
e of
ina*
able
able
able
able
able
le
able
le
le
able
leSES P
eath
e of D
re aft
-stent
aceme
on of d
s)
yoca
t (angi
eriope
nt thro
a pacl
main)ing stent; TP  thienopyridine (ticlopidine or clopidogrel); W  warfarin.
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July 17, 2007:261–7 Long-Term Follow-Up Data of SES Versus BMS in SVGreatment with SES is currently off-label, and also in light of
he results of our trial, potential advantages and drawbacks
f the implantation of SES (or other drug-eluting stents)
ersus BMS in SVG should be carefully evaluated before the
rocedure and discussed personally with every patient.
Our trial also suggests that in SVG there can be a
otential late “catch-up” phenomenon, as a nonsignificant
rend toward more repeated revascularization procedures
ccurred in the SES group after 6 months with respect to
he BMS group, thus leading to a lack of benefit of SES
ver BMS in reduction of clinical restenosis. A percutane-
us treatment with a clear additional benefit over BMS in
VG lesions, which account for up to 10% to 15% of lesions
reated percutaneously in the majority of the catheterization
aboratories (12), is still missing. Of interest, other recent
tudies assessing the clinical impact of drug-eluting stent
ersus BMS in diseased SVG failed to show benefits of the
ormer over the latter (19,20).
A clear pathophysiological explanation for these findings
s lacking. It is well established that the long-term prognosis
f patients with diseased SVG is mainly impacted by
rogression of disease in nonintervened SVG segments
21,22). However, the specific anatomic and pathological
linical Events and Medical Therapy in the 2 Groups at Longest Av
Table 4 Clinical Events and Medical Therapy in the 2 Groups a
BMS (n 
In hospital
Periprocedural myocardial infarction 1 (3
From discharge to 6 months
Death 0
Myocardial infarction 0
TLR 8 (2
TVR 10 (2
After 6 months
Death 0
Myocardial infarction 1 (3
TLR 3 (8
TVR 4 (1
Cumulative events
Death 0
Myocardial infarction 2 (5
TLR 11 (3
TLR lesion-based 13/49 (2
TVR 14 (3
TVR lesion-based 20/49 (4
MACE (without double counting) 15 (4
Other PCI not TLR/TVR-related 14 (3
Medical therapy at follow-up
Double antiplatelet therapy 19 (5
Single antiplatelet therapy 14 (3
No antiplatelet therapy 4 (1
Aspirin 26 (7
Thienopyridine (clopidogrel or ticlopidine) 26 (7
Statin 27 (7
ata are presented as numbers (percentages). *Fisher exact test.
BMS bare-metal stent; MACEmajor adverse cardiac events (death, any myocardial infarctio
evascularization; TVR  target vessel revascularization.esponse of diseased SVG to stent implantation also can tead to processes that conduct to late/very late thrombosis
nd late restenosis in a more pronounced way than what
ccurs in native coronary arteries. Indeed, SVG lesions,
hich are more lipid-rich, softer, and more prone to rupture
han plaques in native coronary arteries, can induce progres-
ion of atherosclerosis and may lead to an enhanced inflam-
atory and thrombotic reaction after deployment of stents;
his can potentially be more pronounced with devices coated
ith drugs and polymers (23–25).
Thus far, the use of BMS should still be considered the
eference percutaneous treatment of SVG and the correct
ontrol arm for future SVG randomized trials, which should
lso be designed bearing in mind the potential occurrence of
ery late (1 year) thrombosis and late (6 months)
estenosis.
tudy limitations There are major limitations in our study.
irst, the sample size of this cohort of patients is small, thus
he results can be underpowered to appropriately address
pecific questions and can be prone to type I and type II
tatistical error. Second, the recommended duration of
ouble antiplatelet therapy was only mandatory for at least
months in our study (although one-half of the population
as still taking acetylsalicylic acid and a thienopyridine up
le Follow-Up
gest Available Follow-Up
SES (n  38) p Value
2 (5%) 0.99*
1 (3%) 0.99*
1 (3%) 0.99*
2 (5%) 0.047*
2 (5%) 0.012*
10 (26%) 0.001*
4 (10%) 0.35*
7 (18%) 0.30*
11 (29%) 0.05
11 (29%) 0.001*
7 (18%) 0.15*
9 (24%) 0.55
9/47 (19%) 0.39
13 (34%) 0.74
17/47 (36%) 0.64
22 (58%) 0.13
12 (32%) 0.57
19 (50%) 0.91
15 (39%) 0.88
4 (10%) 0.97
26 (68%) 0.86
27 (71%) 0.94
29 (76%) 0.74
VR); PCI percutaneous coronary intervention; SES sirolimus-eluting stent; TLR target lesionailab
t Lon
37)
%)
2%)
7%)
%)
%)
1%)
%)
0%)
6%)
8%)
1%)
1%)
8%)
1%)
8%)
1%)
0%)
0%)
3%)o 3 years, as evident in Table 4). Recent evidence has
s
m
l
w
w
3
t
e
“
T
t
fi
p
a
r
a
K
t
l
i
m
c
e
t
t
(
c
C
O
w
S
r
l
i
p
t
m
l
R
t
h
a
R
1
1
1
1
1
266 Vermeersch et al. JACC Vol. 50, No. 3, 2007
Long-Term Follow-Up Data of SES Versus BMS in SVG July 17, 2007:261–7hown that double antiplatelet therapy should be recom-
ended in all patients receiving drug-eluting stents for at
east 12 months (26). On the other hand, the RRISC trial
as started in 2003 and, during that period, patients in
hom SES were implanted, routinely received 2- to
-month double antiplatelet therapy, according also to other
rials (1–4). However, we cannot exclude that some of the
vents described in the current study could be explained by
premature” discontinuation of dual antiplatelet therapy.
hird, this study presents a secondary post-hoc analysis;
hus, the current main end point (death) was not prespeci-
ed at the moment of the beginning of the trial (which was
owered for a 6-month difference in angiographic late loss
nalysis). Death was selected as the end point after the
ecent concerns related to an increase in long-term mortality
fter SES treatment in native coronary arteries (6–10).
However, similar to the BASKET-LATE (Basel Stent
osten Effektivitats—LAte Thrombotic Events) trial (6),
he use of a previously randomized study cohort for a
ong-term observational study can preserve some of the
nternal validity of a randomized comparison (27). Because
ost of the effort and resources go into the organization and
onduct of the original trial, adding a second question and
xtending follow-up can be logistically efficient and scien-
ifically helpful (27). Moreover, no drug-eluting stent trial
o date has been powered to assess long-term mortality
1–4), thus preliminary data on long-term results of the
urrently available trials can be useful for future directions.
onclusions
ur study has shown that the use of BMS was associated
ith lower long-term mortality than the use of SES for
Figure 2 TVR-Free Survival Curves
Kaplan-Meier estimates for target vessel revascularization (TVR)-free survival by
type of randomized stent (dotted blue line  BMS; continuous red line 
SES). Abbreviations as in Figure 1.VG disease. Also, the 6-month reduction in repeatedevascularization procedures shown with the use of SES was
ost at longer-term follow-up. Because the observations seen
n this secondary post-hoc analysis may have arisen from the
lay of chance or other clinical factors unrelated to stent
ype, further studies are required before conclusions can be
ade about the safety or harm of using SES for SVG
esions.
eprint requests and correspondence: Dr. Pierfrancesco Agos-
oni, Antwerp Cardiovascular Institute Middelheim, AZ Middel-
eim, Lindendreef 1, 2020 Antwerp, Belgium. E-mail:
gostonipf@gmail.com.
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